The feasibility of using complexes with cyclodextrins (CDs) in nicardipine (NC) controlled delivery has been examined, with a view to extending the pharmaceutical applications spectrum of these carriers. For a fast release fraction, a hydrophilic b-cyclodextrin derivative (hydroxypropyl-b-cyclodextrin) was employed to form a water-soluble complex. For the sustainedreleasing portion, triacetyl-b-cyclodextrin (TAbCD) was used to provide complexes with appropriate hydrophobicity. An optimal formulation was designed by the combination of each fraction in different mixing ratios. The release behaviour of the complexes, as well as of their mixtures, was examined in simulated gastric (pH 1.2) and intestinal (pH 6.8) fluids. The formulations released the drug rapidly at the initial stage, followed by a slow release. The drug release rate was markedly retarded in the increasing order of the amount of NC / TAbCD complex. When NC was administered to rabbits, its absorption was very rapid with a short elimination half-life, while a prolonged maintenance of the plasma levels was obtained for the two selected formulations. The drug bioavailability was considerably improved especially after the administration of the mixture of hydrophilic and hydrophobic complexes, when compared with the NC / TAbCD complex. The results suggested that the critical combination of hydrophilic and hydrophobic CDs complexes, in appropriate ratios, could be a promising drug delivery system with a prolonged therapeutic effect coupled with a more balanced bioavailability. 
physical, chemical and biological properties of sever-frequency of daily administration [13, 14] . The inal drug molecules, due to their characteristic inclu-corporation of a rapid-dissolving fraction together sion ability [1] [2] [3] . In recent years, various kinds of with a slow-release portion could be advantageous, chemically-derived CDs have been prepared to ex-since the initial release of a certain amount of NC tend the physicochemical and inclusion properties will give more balanced oral bioavailability, reducand also the multi-functional pharmaceutical charac-ing the first-pass metabolism in the liver. teristics of the parent host molecules, their hydroxyl
In the present study, the release behaviour of groups being available as starting points for structur-NC / HPbCD and NC / TAbCD complexes, as well al modification, without eliminating the central cavi-the corresponding mixtures in different molar ratios, ty for guest accommodation [3] . Among the chemi-was evaluated in acidic (pH 1.2) and alkaline (pH cally modified CDs, the hydrophilic CD derivatives, 6.8) media. Furthermore, we have investigated the such as hydroxypropyl-b-CD (HPbCD) and sul-oral bioavailability of the selected formulations in fobutyl ether-bCD, are useful to improve the solu-rabbits. bility, dissolution rate and bioavailability of poorly water-soluble drugs [4] [5] [6] , while hydrophobic CD derivatives, such as ethylated and acylated CDs, have 2 . Material and methods potential as sustained-release carriers of drugs with short half-lives [7] [8] [9] . Furthermore, advanced con-2 .1. Materials trolled release can be achieved by a pertinent hybrid- ising of complexes obtained with hydrophilic and NC, HPbCD (Kleptose HPB , MW|1300, DS hydrophobic CD derivatives. 0.63) and TAbCD were purchased from Effechem We have recently reported [10] that HPbCD is SRL (Italy), Roquette (France) and Sigma-Aldrich particularly useful to improve the low solubility and (Germany), respectively. All other chemicals and dissolution rate of nicardipine (NC) in alkaline solvents were of analytical reagent-grade (Merck and medium. TAbCD was also successfully used to Sigma-Aldrich) and deionised water (Millipore Elix achieve inclusion compounds with NC and a sus-5 system) was used throughout the study. tained drug release profile was observed from these Since NC is light sensitive, almost all experiments hydrophobic complexes [11] . This led us to design a were carried out in a darkroom under yellow light sustained release formulation of NC consisting of a (Philips Powertone SON E27). When this photocombination of both types of complexes: the hydro-protection was impossible to achieve, all suspensions phobic NC / TAbCD complex as the slow-release or samples containing NC were protected from light portion, to provide an appropriate hydrophobicity, by wrapping the vials with aluminium foil. and the highly hydrophilic NC / HPbCD complex as the fast-dissolving fraction.
2 .2. Preparation of inclusion complexes NC, a calcium channel-blocking agent, is an effective drug in the management of mild to moder-The 1:1 guest / host inclusion complexes were ate hypertension, angina pectoris and cerebral dis-prepared by the spray-drying method as previously ease. It was used as model drug since its bioavail-described [10, 11] . Briefly, hydroalcoholic solutions ability is very limited (15-40%) and like other containing equimolar quantities of NC and HPbCD dihydropyridine derivatives, its standard formulation or TAbCD were spray-dried (LabPlant SD-05), undergoes rapid absorption and extensive biotrans-under the following conditions: air flow rate, 50 3 formation in the liver, with a short elimination half-m / h; atomising air pressure, 1.0 bar; inlet temperalife (about 1 h), which often results in significant ture, 160 8C, outlet temperature, 85 8C and flow rate fluctuations in plasma concentrations [12] . To attain of the solution, 400 ml / h. a prolonged therapeutic effect and a reduced inci-Physical mixtures of NC and both CDs, in a 1:1 dence of side-effects, sustained release formulations molar ratio, were also prepared for reference. of NC have been developed to maintain a suitable
The evidence of inclusion complexation between plasma level for a long period of time with minimal NC and HPbCD or TAbCD and the detailed physicochemical characterization of the corre-were immediately separated by centrifugation at sponding complexes were previously reported 3000 rpm for 10 min and stored at 280 8C until [10, 11] .
analysis. Baseline plasma samples obtained prior to Several combinations of both complexes were NC administration at time 0 served as the blank prepared by mixing, in different molar ratios (1:1, control for each animal. 1:2; 1:4, 1:6 and 1:10), the corresponding amounts of
The drug plasma levels were determined by a NC/HPbCD and NC / TAbCD complexes, in a glass previously described high performance liquid chromortar. matography (HPLC) method with UV detection [15] . Briefly, the method involved the addition of the internal standard (nimodipine) to the plasma samples 2 .3. In vitro dissolution studies with subsequent solid phase extraction using C 18 cartridges. The HPLC system consisted of a Hewlett The dissolution profiles of NC from the CDs Packard (Waldbronn, Germany) model 1050 pump, inclusion complexes, as well from the respective equipped with a HP1050 multiple wavelength UV mixtures, were collected using a Vankel VK7000 detector operated at 254 nm, an injector with a 20-ml apparatus, according to the USP rotating basket loop and a HP3396A recording integrator. The  method. The dissolution media consisted of 1000 ml stationary phase was a Licrospher 100 RP-18 of enzyme-free simulated gastric (pH 1.2) and reversed-phase column (250 mm34 mm i.d.; 5 mm intestinal (pH 6.8) fluids (USPXXIV). The stirring mean particle size, Merck) equipped with a guard speed was 10062 rpm and the temperature was column similarly packed and maintained at 30 8C. A maintained at 3760.2 8C. Powdered samples con-mixture of acetonitrile-0.02 M sodium phosphate taining 30 mg of NC or its equivalent were used. At buffer-methanol (45:40:15) with 0.2% triethylamine set time intervals for a period of 8 h, the amount of and at pH 6.1, delivered at a flow rate of 1.2 ml / min, dissolved drug was automatically measured by UV was used as mobile phase. spectroscopy at 357 nm. Dissolution runs were
The method proved to be linear in the range of carried out six times for all samples.
5-100 ng / ml with a regression coefficient of 0.9993. The relative standard deviations of intra-and interday analysis for NC in plasma were 3.26-6.52% 2 .4. Bioavailability studies in rabbits (n55) and 4.71-9.38% (n55), respectively. The differences in the mean value measured from the The bioavailability studies were carried out using concentration prepared, expressed as percentages (% male New zealand albino rabbits with an average bias), were only 25.2, 0.4 and 0.8% at NC conweight of 4 kg, housed individually in standard cages centrations of 5, 25 and 50 ng / ml, which confirmed in a room with air, humidity and temperature control the accuracy of the method. and on a 12-h light, 12-h dark cycle. The animals
The pharmacokinetic parameters extracted from were kept on a standard diet.
the plasma data were calculated using noncompar- At least 12 h prior to drug administration, the tmental analysis (WinNonlin , Version 1.1) and animals were fasted but had free access to water. NC included the maximum plasma concentration (C ), max and the two selected formulations were administered the time to reach the maximum plasma concentration orally to six animals, at a dose of 15 mg / kg, with a (T ), the area under the drug plasma concen- complexation between NC and this CD in alkaline effects. However, in the slow-release-type preparamedia, as previously reported [10] . The significant tions there is usually a lag time for reaching an enhancement of the low dissolution properties of NC effective blood level of drug. For this reason, an from the NC / HPbCD spray-dried complex has been initial rapid release would be necessary to avoid this attributed to: (1) surfactant-like properties of the lag time and offer a more balanced bioavailability. carrier, which can reduce the interfacial tension
To gain a rapid appearance of NC in the blood and to between water-insoluble drugs and the dissolution maintain a constant drug level for a long period of medium; (2) an increase in NC solubility upon time, we decided to hybridise a fast-releasing fraccomplexation in the solid state; (3) the high ener-tion with the slow-releasing NC / TAbCD complex. getic amorphous state following complexation, as
Because of the poor aqueous solubility and wettabiliconfirmed by previous X-ray diffractometry studies ty of NC, we employed the highly water-soluble [5, 16, 17] .
NC / HPbCD complex as the immediate-release com-On the other hand, it was clearly observed that the pound, in the expectation of an enhanced initial dissolution rate of NC, in both dissolution media, release rate of NC. was markedly retarded by complexation with the Thus, in the next step, an optimisation of the hydrophobic TAbCD, mainly due to the poor water release profile of NC was attempted by the combinasolubility of this complex. Indeed, a total release of tion of the HPbCD and TAbCD spray-dried com-NC at pH 1. fraction, according to zero-order kinetics. Indeed, the 3 .2. Bioavailability studies in rabbits drug release occurred in two stages: faster release in the initial stage (up to 1 h) and slower release in the The mean plasma concentrations of NC following second stage. Compared to NC alone, the drug a single oral dose of the plain drug, formulation I release rate from all these formulations was sig-(mixture of HPbCD and TAbCD complexes in a nificantly suppressed, a result of the retarding effect molar ratio of 1:4) or formulation II (TAbCD of the hydrophobic complex in the mixture. In complex), equivalent to 15 mg / kg, are shown in Fig.  contrast , the increase in the initial dissolution rate 5. The pharmacokinetic parameters calculated for the appeared to be proportional to the molar ratio of the six animals are summarized in Table 1 . fast-dissolving faction, i.e. NC / HPbCD complex, in the formulations (1:10,1:6,1:4,1:2,1:1).
It was evident from these results that the NC release rate could be critically modified by changing the mixing ratio of the hydrophilic and hydrophobic CD inclusion complexes.
From inspection of the dissolution profiles, among the various combinations, the 1:4 mixture of both complexes, namely formulation I, seemed to be suitable for our purpose with regard to the release pattern and release time. This formulation provided a sufficiently slow release of the drug for a long period of time following an initial rapid dissolution (about 40% drug release at stomach pH). A sufficient release of drug in the early stage would be necessary Each value represents the mean6S.E., with the exception of the T parameter, which is represented by the median. max The absorption of NC in rabbits was very rapid for II, which could explain the sparing increase in the the plain drug, with a time to reach the maximum AUC of the later. This behaviour was probably 0-24 h plasma level (69.64 ng / ml) of 1 h. This drug showed due to the extremely slow dissolution rate of the a short elimination half-life (1.60 h), reflecting its NC / TAbCD complex. rapid disappearance in the plasma of the animals and From the inspection of these results, we could the concentration could not be detected after 8 h, verify that the in vitro release behaviours were being below the minimum detection limit of 5 ng / partially reflected in the plasma levels after the ml. The plasma concentrations of NC after oral administration of the corresponding formulations. administration of both formulations did not show a For example, NC gave an initial rapid increase in sharp peak and the corresponding times to reach the plasma drug levels, followed by a rapid decrease. maximum plasma level were significantly prolonged,
The sustained plasma levels of the drug observed for 3 and 4 h for formulations I and II, respectively. a long period when formulations I and II were Also, the plasma concentrations were maintained at a administered reflected their slow in vitro release relatively constant level for a long period when the pattern. Formulation I gave an initial rapid increase drug was administered as the two formulations, in the drug plasma level, followed by its maintepresenting a somewhat sustained-release pattern. nance at a relatively constant level, which could be However, the plateau obtained in the drug plasma well correlated with the two stages of the in vitro concentrations was more evident after the adminis-drug release mentioned above. Compared to the tration of formulation II. In addition, the MRT values hydrophobic complex alone, formulation I produced displayed by formulations I and II were about 3.5-a faster initial increase in the NC plasma level, fold larger than that of NC alone, confirming the which could reflect the presence of the hydrophilic sustained-release behaviour of these preparations in complex, in a perfect correlation with the in vitro the rabbit model. However, no significant difference release profiles. in the MRT values was observed between the two The attenuation of the initial high peak of the drug formulations.
plasma concentrations, after the administration of the It was interesting to note that there was a 3.2-and selected formulations, suggested that the frequency 1.6-fold increase in the AUC value for formula-and severity of NC side-effects could also be re-0-24 h tions I and II, respectively, corresponding to a duced. Further, the formulation constituted by the greater extent of oral absorption when compared combination of HPbCD and TAbCD complexes with the drug alone. This increase in the AUC produced retarding effects with superior oral bio-0-24 h may be due to a longer residence time of these availability compared with NC and the hydrophobic formulations in the gastrointestinal tract, as was TAbCD complex alone. suggested by their larger MRT and T values. The max difference in the AUC between formulations I 0-24 h and II was also found to be statistically significant 4 . Conclusions (P,0.05). The drug plasma levels in the initial stage after the administration of formulation I were mark-
The NC release rate could be controlled by edly higher than the levels obtained for formulation adjusting the mixing ratio of its hydrophilic
